New hope for tough cancers: first patients try experimental drug
Disease control
Terminated
This early-stage study tested a new experimental drug called ACTM-838 in patients with advanced solid tumors that had stopped responding to standard treatments. The first part aimed to find the safest and most effective dose, while the second part planned to test that dose in mor…
Phase: PHASE1 • Sponsor: Actym Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC